On a remarkable day at the Hyatt Regency San Francisco on November 8, industry leaders, medical professionals, and innovators gathered to explore the future of heart care at the Next Generation Total Artificial Heart: SynCardia TAH Product Briefing. This exclusive event, co-hosted by SynCardia and the US Unicorn Foundation (USUF), highlighted groundbreaking advancements in artificial heart technology and reinforced the shared mission of supporting life-saving innovations for heart failure patients.
About the US Unicorn Foundation
The US Unicorn Foundation is a nonprofit organization dedicated to empowering minority entrepreneurs and supporting small businesses in achieving sustainable growth. Our mission is to provide resources, mentorship, and guidance to help these businesses navigate complex challenges and realize their full potential in today’s market. From early-stage support to financial planning, we work alongside companies to strengthen their foundations, uplift communities, and foster economic resilience. With a network of experienced advisors and partners, we are committed to creating pathways for underserved entrepreneurs, helping them thrive and contribute meaningfully to society.
SynCardia: Saving Lives, One Heart at A Time
SynCardia stands as the sole manufacturer and provider of the world’s only commercially approved total artificial heart, a technology that continues to transform the lives of patients with end-stage heart failure. When a donor heart is unavailable, SynCardia offers a temporary heart solution that can keep patients alive until a suitable donor heart becomes available. The SynCardia Total Artificial Heart (TAH) is the only FDA-approved device of its kind, providing critical support to patients who are too sick to wait for a transplant.
Since its introduction, the SynCardia TAH has helped extend over 750 years of patient life across the globe, with more than 2,100 successful implants performed to date. SynCardia’s device is particularly vital in addressing the worldwide shortage of donor hearts, offering hope to patients at risk of death or becoming too ill for transplant surgery. The company’s mission is simple but powerful: to give patients the priceless gift of more time.
A Day of Innovation and Insight
The event provided a platform for deep discussions and presentations on the state of heart health and the future of artificial heart technology. Attendees had the unique opportunity to hear from leading experts, including SynCardia’s team and guest speakers who are directly involved in advancing heart care.
We were honored to invite Johnny Lemucchi, a former SynCardia Total Artificial Heart recipient, to share his powerful story. Johnny, now with a human donor heart, continues to be an active supporter of Unique Beating Hearts (UBH), a nonprofit organization that connects and supports people who have experienced the journey of heart failure and artificial heart implantation. His inspiring story underscores the life-changing impact of SynCardia’s technology on individuals and families.
We also welcomed Dr. Francisco Arabia, a thoracic surgeon specializing in advanced cardiac care. Dr. Arabia has authored over 100 research publications and has been instrumental in advancing the field of artificial hearts. His work continues to shape the future of heart health, and we were grateful for the insights he shared during the event.
A Step Toward a Healthier Future
This event was a significant step forward in highlighting the life-saving potential of SynCardia’s Total Artificial Heart. By gathering key thought leaders, healthcare professionals, and innovators, we collectively moved closer to understanding how this technology can revolutionize heart care and improve patient outcomes worldwide.
As SynCardia continues to innovate and grow, it remains committed to enhancing the lives of heart failure patients around the globe. Through partnerships with hospitals in over 20 countries and ongoing advancements in medical technology, SynCardia is setting the stage for a future where heart failure patients no longer have to wait for a transplant, and where innovation drives life-saving solutions.
As SynCardia continues to innovate and grow, it remains committed to enhancing the lives of heart failure patients around the globe. Through partnerships with hospitals in over 20 countries and ongoing advancements in medical technology, SynCardia is setting the stage for a future where heart failure patients no longer have to wait for a transplant, and where innovation drives life-saving solutions.
Comments